Prospective Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2015; 21(25): 7869-7876
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7869
Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis
Yan Xu, Yong-Gui Zhang, Xu Wang, Wen-Qian Qi, Shao-You Qin, Zhen-Hua Liu, Jian Jiao, Jiang-Bin Wang
Yan Xu, Yong-Gui Zhang, Xu Wang, Wen-Qian Qi, Shao-You Qin, Zhen-Hua Liu, Jian Jiao, Jiang-Bin Wang, Department of Gastroenterology, China-Japan Union Hospital, Jilin University, Changchun 130033, Jilin Province, China
Author contributions: Xu Y, Zhang YG and Wang JB designed the research; Wang X and Liu ZH performed the research; Zhang YG, Qi WQ and Jiao J contributed new reagents or analytic tools; Xu Y and Qin SY analyzed the data; Xu Y and Zhang YG wrote the paper.
Supported by Grant from the Youth scientific research fund, No. 2013207059.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other people or organizations that could inappropriately influence our work; there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented herein.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jiang-Bin Wang, Professor, Department of Gastroenterology, China-Japan Union Hospital, Jilin University, No. 126 Xiantai Dajie, Changchun 130033, Jilin Province, China. yongguizhangcn@126.com
Telephone: +86-431-84995303 Fax: +86-431-84641026
Received: August 20, 2014
Peer-review started: August 21, 2014
First decision: November 14, 2014
Revised: March 4, 2015
Accepted: May 11, 2015
Article in press: May 11, 2015
Published online: July 7, 2015
Core Tip

Core tip: Entecavir is a potent antiviral agent that is effective and safe for the treatment of chronic hepatitis B. However, data on its clinical benefits in patients with cirrhosis, especially in long-term treatment, are limited. The aims of this prospective study were to evaluate the antiviral efficacy and clinical outcomes of entecavir treatment for 240 wk in nucleoside-naive Chinese patients with chronic hepatitis B, and compensated or decompensated cirrhosis.